Cellular diversity and genetic alterations in light chain amyloidosis and amyloidosis with co-occurring multiple myeloma
Srivastava, A.; Kumari, R.; Miettinen, J. J.; Suvela, M. H.; Acs, K.; Luoma, S.; Heckman, C. A.
Show abstract
Immunoglobulin light-chain amyloidosis (AL) has been reported to be associated with multiple myeloma (MM) in approximately 10-15% of cases, with the two conditions often coexisting. Understanding the interaction between these diseases is vital for improving patient outcome and developing targeted treatments. Our study investigates cellular heterogeneity in immunoglobulin light-chain amyloidosis (AL) and coexisting multiple myeloma (MM) or monoclonal gammopathy of undetermined significance (MGUS) (AL_MM) using single-cell RNA sequencing (scRNA-seq). A total of 21 bone marrow samples from 20 patients were analyzed, including 9 with AL_MM. We observed exclusive association of the 1q gain chromosomal aberration with the AL_MM group (p<0.01). The scRNA-seq data revealed 27 distinct cell clusters representing 14 unique cell types, with 6 clusters identified as plasma cell (PC) subpopulations. These subpopulations exhibited considerable inter- and intra-individual heterogeneity. Comparative analysis between the AL and AL_MM groups showed higher proportions of GMP, HSC, cDC2, and T cells in the AL group (p<0.05), suggesting a distinct tumor microenvironment. Differential gene expression analysis between the two groups identified 152 up-regulated and 134 down-regulated genes in AL_MM samples, with 28 of the up-regulated genes and 1 downregulated gene located on chromosome 1q. Furthermore, the application of inferCNV to the scRNA-seq data revealed amplifications in chromosome 4, 7, 11, 20, and 22 of AL samples. Our findings enhance the understanding of the molecular mechanisms underlying AL and its progression in patients with coexisting MM or MGUS. The study provides valuable insights into disease progression and cellular variability, supporting improved patient stratification and the development of targeted therapies for these complex hematological conditions. KEY POINTSO_LI1q gain is mainly restricted to amyloidosis patients with co-occurring sMM, MM, or MGUS. C_LIO_LIMultiple genes located on chromosome 1 are upregulated in plasma cells of patients with co-occurring AL and MM, potentially contributing to disease progression. C_LI
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- High WEE1 expression is independently linked to poor survival in multiple myeloma 95%
- Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival 93%
- Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry 92%
Similar papers in this journal
- Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma 94%
- Single-cell profiling identifies clinically relevant interactions between tumor associated macrophages and blood endothelial cells in diffuse large B cell lymphoma 92%
- Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies 92%
Similar papers in this journal
- Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response 92%
- Validation of the IMPEDE VTE Score for Prediction of Venous Thromboembolism in Multiple Myeloma: A Retrospective Cohort Study 91%
- COVID symptoms, testing, shielding impact on patient reported outcomes and early vaccine responses in individuals with multiple myeloma 90%
Similar papers in this journal
Similar papers in this journal
- Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 As Marker of Aggressive Disease 94%
- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting 93%
- Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.